Serrated polyps and polyposis of the colon: a brief review for surgeon endoscopists

Historically, all serrated polyps (SPs) were thought to be benign, clinically unimportant lesions. However, it is now recognized that through the serrated neoplasia pathway (SNP), SPs play a role in the development of 15%–30% of cases of colorectal cancers (CRCs). Furthermore, a high proportion of postcolonoscopy CRCs are believed to arise from SNP. Serrated polyps are classified into hyperplastic polyps, sessile serrated lesions, sessile serrated lesions with dysplasia, traditionally serrated adenomas, and unclassified serrated adenoma, each with a distinct morphological and molecular profile. Despite improved understanding, SPs remain a clinical challenge owing to evolving terminology, frequent pathologic misclassification, endoscopic underdetection, and high rates of incomplete removal. Surgeon endoscopists and surgeons who perform colorectal procedures will undoubtedly come across patients with SPs, and this paper summarizes some of the clinical challenges they will encounter. We also discuss the diagnosis and management of patients with serrated polyposis syndrome (SPS).

Confusing terminology

The term “serrated” describes a sawtooth folding of the crypt epithelium found in SPs (Figure 1). In the past, all SPs were classified as hyperplastic polyps (HPs) and were thought to have no malignant potential. However, subsequent studies described HPs with dysplasia and used the term “serrated adenoma.” These HPs with dysplasia were later renamed “traditional

Summary

Serrated polyps (SPs) were once considered benign, clinically unimportant lesions. However, it is now recognized that up to 30% of sporadic colorectal cancers (CRCs) may arise from SPs via the serrated neoplasia pathway (SNP), a distinct carcinogenesis pathway separate from the traditional adenoma–cancer sequence.1 Despite their importance, the diagnosis and management of SPs remain challenging for several reasons. First, the terminology for SPs continues to evolve, which can lead to confusion with regards to malignant potential and management. Second, because SPs are difficult to visualize on colonoscopy, endoscopic detection and removal rates can be poor. Third, there can be wide variations in the pathologic interpretation of SPs owing to subtle differences in histomorphologic characteristics.

Finally, as understanding of the natural history of SPs continues to evolve, surveillance guidelines are inconsistent among organizations and are largely based on low-quality evidence.

It is imperative that surgeon endoscopists and surgeons who perform colorectal procedures stay up to date with the current literature regarding SPs, as they will undoubtedly care for patients with SPs. Here we discuss the diagnosis and management of SPs, organized by specific clinical challenges that surgeons may face. Key practice points are summarized in Box 1. We also provide a brief overview of serrated polyposis syndrome (SPS).
serrated adenomas” (TSAs), to distinguish them from other, more common subtypes of SPs.

In 2019, the World Health Organization (WHO) proposed 5 subtypes of serrated polyps: HPs, microvesicular type or goblet cell-rich type; sessile serrated lesion (SSL); sessile serrated lesion with dysplasia (SSLD); TSA; and serrated adenoma, unclassified.1 Although the histopathological features of HP subtypes have been well studied, there is no obvious impact of this distinction on clinical management. With regards to SSLs, it is important to note that term has replaced the former terms “sessile serrated adenoma” or “sessile serrated polyp” because SSLs may not have dysplasia on histology nor be polypoid in morphology. The term “SSA,” because “adenoma” intrinsically implies presence of dysplasia, which SSLs may not necessarily have. The term “SSP” is also inaccurate since most SPs are flat rather than have “polypoid” morphology. An additional subtype of serrated adenoma unclassified is reserved to describe dysplastic polyps that are difficult to distinguish as either SSLD or TSA.

**DIFFICULTY IN HISTOPATHOLOGIC INTERPRETATION**

Serrated polyps are differentiated by architectural characteristics rather than by nuclear changes, which characterize traditional dysplasia seen in adenomatous polyps (Figure 1).

True HPs show no or minimal cytologic atypia. They are considered benign with no significant malignant potential. In contrast, approximately 15% of SSLs show dysplastic features and, as such, SSLs are considered premalignant lesions. The pathologist will usually make explicit mention of dysplasia within an SSL in their report when it is present. Although dysplasia can be graded as low or high in SSLs, the clinical significance of this distinction is unknown. Therefore, any presence of dysplasia in SSLs (SSLDs) is managed like high-grade dysplasia in the conventional adenomatous polyp. Traditional serrated adenomas have low-grade dysplasia by definition, and only high-grade dysplasia is reported separately.

There are considerable histologic similarities between HPs and SSLs, which can lead to misclassification. A
Canadian study reviewed 4096 pathology reports and reclassified 17% of proximal HPs and 20% of HPs larger than 5 mm in size as SSLs. Location in the proximal colon and size larger than 5 mm were independently associated with HPs being reclassified as SSLs. This study reinforces the high level of caution needed when diagnosing or interpreting findings of any proximal and/or large SPs. It further underscores the importance of clear communication between endoscopists and pathologists regarding the location and size of any excised polyps on pathology requisition forms.

**LOW ENDOCOSPIC DETECTION AND REMOVAL RATES**

The endoscopic features of HPs include small size (usually < 5 mm); pale, smooth appearance; and sessile morphology (Figure 2). Sessile serrated lesions are commonly found in the right colon and are pale with flat morphology and irregular borders (Figure 2). Because of excessive mucin production, most SSLs are covered with a thin mucous cap with a rim of debris. Traditional serrated adenomas have either sessile or pedunculated morphology with a pine-cone-like appearance.

**Endoscopic detection**

Many SPs are challenging to detect with endoscopy given their flat morphology, pale colour (which merges with the surrounding mucosa), indistinct border, and mucous covering. The endoscopic SP detection rate (SDR) has been shown to vary widely, even among expert endoscopists, raising a concern that many premalignant SPs are being underdetected. Kahi and colleagues showed that among 15 endoscopists the SDR varied from 1% to 18%, which was far greater than the variability in adenoma detection rates (ADRs) among the same endoscopists. Although ADR for screening colonoscopy is an important quality indicator, there is no clear benchmark for SDR. It is possible that SDR will become a colonoscopy quality measure on its own or in conjunction with ADR in the future.

As SPs are easily missed on endoscopy, many studies have assessed additional endoscopy modalities, including chromoendoscopy and narrow-band imaging (NBI), to improve SDR. Pan-colonic chromoendoscopy is associated with a higher SDR than conventional colonoscopy, but the additional time required for this technique limits its use in routine screening. In contrast, NBI surveillance has not been found to decrease SP miss rates.

**Endoscopic removal**

Given the potential for malignant transformation, it is recommended that all SPs be completely removed during colonoscopy, except for small (< 5 mm), multiple lesions in the sigmoid or rectum that are suspected to be HPs. Multiple diminutive rectosigmoid lesions should still be biopsied randomly to rule out more advanced SPs.

Serrated polyps smaller than 10 mm can generally be removed using standard snare polypectomy techniques. However, as SSLs have flat morphology with indistinct borders, they are more prone to incomplete resection than conventional adenomas. For SPs larger than 10 mm, endoscopic mucosal resection (EMR) involving submucosal saline injection to lift the lesion followed by snare polypectomy with electrocautery is safe and effective.

Submucosal injection of methylene blue before polypectomy may help endoscopists better visualize the borders of SPs to ensure their complete removal (Figure 3).

**Alternative methods for detecting serrated polyps**

Aside from colonoscopy, other screening modalities for CRC include stool tests and computed tomography colonography (CTC), and have limited use for SP detection. A study involving asymptomatic patients undergoing concurrent fecal immunochemical test (FIT) and colonoscopy, showed a poor SDR for FIT, even for large SSLs. Accurate visualization of SPs during CTC is challenging owing to their flat morphology. A randomized trial
involving 8844 patients showed that colonoscopy had a significantly higher SSL detection rate than CTC (4.3% v. 0.8%). Although CTC is commonly performed after an incomplete colonoscopy, it is important to be aware of its limitation in detecting SPs.

Surveillance guidelines based on weak evidence

Multiple societies and expert panels have published guidelines for follow-up intervals for SPs (Table 1). However, current guidelines are based on weak evidence, as there is limited knowledge regarding “dwell time” or how long it takes for premalignant SPs to become CRC.

Most current guidelines recommend a surveillance interval of 3 years for patients with SSLs 10 mm or larger or with dysplasia, for patients with 3 or more SSLs smaller than 10 mm, or for patients with TSAs of any size, which is consistent with the recommendations for high-risk or advanced adenomas. Canadian and American guidelines also recommend a surveillance interval of 5 years for patients with fewer than 3 SSLs smaller than 10 mm.4

There are inconsistencies among guidelines for HPs, particularly for large or right-sided HPs. The US Multi-Society Task Force on Colorectal Cancer guideline recommends a screening interval of 10 years for individuals with HPs and no other synchronous lesions, consistent with average-risk populations.8 On the other hand, the Canadian Association of Gastroenterology guidance makes no specific reference to HP surveillance guidelines at all.7 However, as previously discussed, approximately 20% of HPs located in the proximal colon and/or larger than 5 mm have been shown to be SSLs when re-examined by an expert pathologist.2 Findings such as these have led other groups to recommend more aggressive surveillance, particularly for large HPs. A primarily US-based expert panel considered large (> 10 mm) HPs as intermediate risk and recommended 5-year surveillance intervals for these lesions.3 Some experts endorse that all SPs proximal to the sigmoid colon and all SPs of the rectosigmoid colon larger than 5 mm should be considered equivalent to SSL and be removed. Given the greater chance for histopathological misdiagnosis, when proximal HPs larger than 5 mm are diagnosed, the endoscopist should consult with the pathologist when making surveillance decisions.

Serrated polyposis syndrome

Serrated polyposis syndrome is characterized by the appearance of multiple SPs throughout the colon. In 2019, the WHO updated their clinical criteria for the diagnosis of SPS (Table 2).

Individuals with SPS have a higher risk of CRC, with some studies reporting a 40%–50% lifetime risk. First-degree relatives of patients with SPS are also at increased risk for both SPS and CRC. Given the increased risk for CRC, patients with SPS with intact colons are generally recommended to undergo annual surveillance (Table 1). A screening colonoscopy is recommended for first-degree relatives starting at age 40 years or at 10 years younger than the age at diagnosis of the youngest affected relative, whichever is earlier. Surgery is indicated for patients with SPS when polyps cannot be managed by endoscopic intervention or when CRC is diagnosed. There is, however, a paucity of data regarding the surgical management of patients with SPS. A study by Edelstein and colleagues reported that with follow-up of on average 5.3 years, 12 of 44 (27%) patients with SPS underwent surgery.10 Of these patients, 8 (66%) underwent colectomy with ileorectal anastomosis (IRA) and 6 (33%) underwent right hemicolectomy. Interestingly, during postoperative surveillance, 4 of 7 (57%) were found to have SSLs or adenomas in the remaining colon/rectum (mean 2.5 yr). Long-term oncologic or survival outcomes were not reported.

There is no clear consensus on the optimal extent of surgery required for individuals with SPS. At the very least, surgical resection requires resection of affected segments harbouring lesions that are not amenable for endoscopic removal (to normal colon or at least a point of minimal disease that can be managed endoscopically).
When disease is limited to 1 colonic segment, a segmental resection can be considered and appears very reasonable based on current evidence. We favour this approach, as there are no compelling data to support resection of clinically unaffected segments on a routine basis. An alternate option includes a total colectomy to prevent future polyps or CRC elsewhere in the colon, but this must be balanced with patient preferences, comorbidities, and gastrointestinal functional outcomes. Finally, both SSLs and adenomas can develop in short intervals after surgery, thus patients with an intact colon/rectum need continued endoscopic surveillance postoperatively.

**Table 1. Summary of current guidelines for surveillance intervals after endoscopic removal of serrated polyps**

<table>
<thead>
<tr>
<th>Histology</th>
<th>Size</th>
<th>Number</th>
<th>Location</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>HP</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Rectosigmoid</td>
<td>International Serrated Lesions Expert Panel⁹</td>
</tr>
<tr>
<td>HP</td>
<td>&lt; 5 mm</td>
<td>Any</td>
<td>Proximal to sigmoid</td>
<td>CAG Working Group⁷</td>
</tr>
<tr>
<td>HP</td>
<td>&gt; 5 mm</td>
<td>Any</td>
<td>Proximal to sigmoid</td>
<td>United States MSTF⁸</td>
</tr>
<tr>
<td>HP</td>
<td>&gt; 10 mm</td>
<td>Any</td>
<td>Proximal to sigmoid</td>
<td>NS</td>
</tr>
<tr>
<td>SSL</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>SSL</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>SSL</td>
<td>&gt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>SSL with dysplasia</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>TSA</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>TSA</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>TSA</td>
<td>&gt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>SPS</td>
<td>See details†</td>
<td>see details†</td>
<td>see details†</td>
<td>NS</td>
</tr>
<tr>
<td>Adenomatous polyp</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>Adenomatous polyp</td>
<td>&lt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>Adenomatous polyp</td>
<td>&gt; 10 mm</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>Adenomatous polyp</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
<tr>
<td>Adenomatous polyp with HGD or villous features</td>
<td>Any</td>
<td>Any</td>
<td>Any</td>
<td>NS</td>
</tr>
</tbody>
</table>

CAG = Canadian Association of Gastroenterology; HGD = high-grade dysplasia; HP = hyperplastic polyp; MSTF = Multisite Task Force; NR = no recommendation; NS = no surveillance; SPS = serrated polyposis syndrome; SSL = sessile serrated lesion; TSA = traditional serrated adenoma; WHO = World Health Organization.

*International expert panel guideline states that depending on the size of the lesion, the confidence in complete endoscopic resection and other associated lesions, intervals shorter than 3 yr can be considered.

†The WHO 2019 diagnostic criteria define SPS as presence of any 1 of these features: presence of at least 5 SPs proximal to the sigmoid colon, all > 5 mm in size with at least 2 > 10 mm in size; presence of > 20 SPs of any size distributed throughout the colon, with > 5 being proximal to the rectum.

‡Annual colonoscopy with intent to clear the proximal colon of all SPs or all SPs with size ≥ 5 mm. If subsequent examination indicates loss of control or progressive control of the polyp burden, then the surveillance interval can be altered.

§Canadian guideline indicates if > 10 adenomatous polyps were found then follow-up colonoscopy should be performed in 1 yr.

**Table 2. World Health Organization (WHO) 2019 clinical criteria for the diagnosis of serrated polyposis; presence of any criterion is required for the diagnosis of serrated polyposis**

<table>
<thead>
<tr>
<th>Criterion 1</th>
<th>Presence of at least 5 SPs proximal to the sigmoid colon, all 5 mm in size with at least 2 being &gt; 10 mm in size</th>
<th>International Serrated Lesions Expert Panel⁹</th>
<th>CAG Working Group⁷</th>
<th>United States MSTF⁸</th>
</tr>
</thead>
<tbody>
<tr>
<td>Criterion 2</td>
<td>Presence of more than 20 SPs of any size distributed throughout the colon with &gt; 5 being proximal to the rectum</td>
<td>International Serrated Lesions Expert Panel⁹</td>
<td>CAG Working Group⁷</td>
<td>United States MSTF⁸</td>
</tr>
</tbody>
</table>

SP = serrated polyp.

*Final polyp count includes any SPs (hyperplastic polyp, sessile serrated lesion with or without dysplasia, traditional serrated adenoma, and unclassified serrated adenoma) and cumulative over multiple colonoscopies.

**CONCLUSION**

Serrated polyps pose a clinical challenge to surgeons and surgeon endoscopists because of changing terminology, difficulty in endoscopic detection and resection, and frequent histopathological misinterpretation. Given the challenges posed in detecting SPs, high-quality colonoscopic examinations are paramount, especially when assessing the proximal colon. When SPs are detected during colonoscopy, they must be removed completely except for small (< 5 mm), multiple lesions in the sigmoid or rectum that are suspected to be HPs. In order to optimally manage patient surveillance and care, it is imperative for surgeon endoscopists to understand the new terminology for serrated lesions, understand their natural history, and communicate with their pathologist if there is risk of misclassification.

**Affiliations:** From the Department of Surgery, Dalhousie University, Halifax, NS (Hyun); the Department of Surgery, University of Manitoba, Winnipeg, Man. (Helewa, Park); the Department of Medicine, University of Manitoba, Winnipeg, Man. (Singh); and the Department of Pathology, University of Manitoba, Winnipeg, Man. (Wightman).

**Competing interests:** None declared.

**Contributors:** All authors contributed substantially to the conception, writing and revision of this article and approved the final version for publication.
References


